Neumora Therapeutics, Inc. Common Stock
NMRANeumora Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for central nervous system (CNS) disorders. It leverages innovative neuroscience science and digital health tools to create precision medicines aimed at improving outcomes for patients with neurological and psychiatric conditions.
Company News
Three clinical-stage biotech companies are leveraging AI to advance drug discovery and treatment in areas like aging, neuroscience, and oncology, with promising platforms that use machine learning to analyze complex biological data.
Neumora Therapeutics will host a virtual R&D Day on October 27, 2025, highlighting its pipeline of novel neurological treatments, including a potential NLRP3 inhibitor for obesity and a vasopressin receptor antagonist for Alzheimer's disease agitation.
Neumora Therapeutics, Inc. is being investigated for potential securities fraud violations after its experimental depression treatment failed the first of three planned studies, causing an 81.42% drop in its stock price.
Regeneron (REGN) and Sage Therapeutics (SAGE) are in focus on regulatory and pipeline updates.
